One treatment a year.
Developing long lasting retinal treatments that are truly transformational for patients with sight-threatening diseases.
Significant unmet needs remain for retinal patients
The overall prevalence of retinal disease continues to be a significant public health challenge. Millions of patients suffering these diseases can experience impaired vision or total loss of sight.
Current treatments typically only address one mechanism of retinal disease and may contribute to a suboptimal or non-response. There is a significant patient population that is unresponsive or becomes refractory to current treatments.
Current retinal treatments across indications require frequent intravitreal injections which places significant demands on patients, clinicians, and healthcare systems. This demanding treatment regimen invariably leads to missed appointments, patient drop-out, and suboptimal treatment outcomes.
Oxular’s technology is devised to change the way retinal patients are treated
Oxular’s innovative treatment approaches are designed to address patients' unmet needs
Oxular’s technologies are designed to address the unmet needs of large patient populations.
Oxuspheres™ are designed to suit the unique ocular environments into which they are delivered, resulting in better drug distribution and longer-lasting treatment effects.
Building lasting value
Oxular’s leadership is committed to developing treatments that are truly life-changing for patients suffering from sight-threatening diseases. The company is well positioned to drive its future growth as a clinical-stage retinal therapeutics company.
Best-in-class R&D capability and technology
Strong leadership with proven track record
Value-added relationships with industry partners
Strong syndicate of knowledgeable healthcare investors
Oxular’s development pipeline includes treatments for prevalent retinal diseases and rare and orphan conditions, including delivery of gene therapy.